Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Aug
31
Today In Oncology
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo